Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression.

Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, Greco L, Pitrone C, Valtorta E, Mauri G, Truini M, Dall'Olio FG, Brandi G, Sartore-Bianchi A, Ricciardiello L, Torri V, Rimassa L, Siena S, Mantovani A, Malesci A, Laghi L; Alleanza contro il Cancro (ACC) Colorectal Cancer Working Group.

Cancer Immunol Res. 2019 May;7(5):751-758. doi: 10.1158/2326-6066.CIR-18-0661. Epub 2019 Feb 25.

PMID:
30804005
2.

Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Grizzi F, Basso G, Borroni EM, Cavalleri T, Bianchi P, Stifter S, Chiriva-Internati M, Malesci A, Laghi L.

Inflamm Res. 2018 May;67(5):375-389. doi: 10.1007/s00011-017-1128-1. Epub 2018 Jan 10. Review.

PMID:
29322204
3.

Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer.

Malesci A, Bianchi P, Celesti G, Basso G, Marchesi F, Grizzi F, Di Caro G, Cavalleri T, Rimassa L, Palmqvist R, Lugli A, Koelzer VH, Roncalli M, Mantovani A, Ogino S, Laghi L.

Oncoimmunology. 2017 Jul 12;6(12):e1342918. doi: 10.1080/2162402X.2017.1342918. eCollection 2017.

4.

Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.

Cavalleri T, Angelici L, Favero C, Dioni L, Mensi C, Bareggi C, Palleschi A, Rimessi A, Consonni D, Bordini L, Todaro A, Bollati V, Pesatori AC.

PLoS One. 2017 May 4;12(5):e0176680. doi: 10.1371/journal.pone.0176680. eCollection 2017.

5.

Urinary chromium is associated with changes in leukocyte miRNA expression in obese subjects.

Dioni L, Sucato S, Motta V, Iodice S, Angelici L, Favero C, Cavalleri T, Vigna L, Albetti B, Fustinoni S, Bertazzi P, Pesatori A, Bollati V.

Eur J Clin Nutr. 2017 Jan;71(1):142-148. doi: 10.1038/ejcn.2016.197. Epub 2016 Oct 12.

6.

BDNF rs6265 methylation and genotype interact on risk for schizophrenia.

Ursini G, Cavalleri T, Fazio L, Angrisano T, Iacovelli L, Porcelli A, Maddalena G, Punzi G, Mancini M, Gelao B, Romano R, Masellis R, Calabrese F, Rampino A, Taurisano P, Di Giorgio A, Keller S, Tarantini L, Sinibaldi L, Quarto T, Popolizio T, Caforio G, Blasi G, Riva MA, De Blasi A, Chiariotti L, Bollati V, Bertolino A.

Epigenetics. 2016;11(1):11-23. doi: 10.1080/15592294.2015.1117736. Epub 2016 Feb 18.

7.

Effects of particulate matter exposure on multiple sclerosis hospital admission in Lombardy region, Italy.

Angelici L, Piola M, Cavalleri T, Randi G, Cortini F, Bergamaschi R, Baccarelli AA, Bertazzi PA, Pesatori AC, Bollati V.

Environ Res. 2016 Feb;145:68-73. doi: 10.1016/j.envres.2015.11.017. Epub 2015 Dec 6.

8.

Susceptibility to particle health effects, miRNA and exosomes: rationale and study protocol of the SPHERE study.

Bollati V, Iodice S, Favero C, Angelici L, Albetti B, Cacace R, Cantone L, Carugno M, Cavalleri T, De Giorgio B, Dioni L, Fustinoni S, Hoxha M, Marinelli B, Motta V, Patrini L, Pergoli L, Riboldi L, Rizzo G, Rota F, Sucato S, Tarantini L, Tirelli AS, Vigna L, Bertazzi P, Pesatori AC.

BMC Public Health. 2014 Nov 4;14:1137. doi: 10.1186/1471-2458-14-1137.

9.

Blood DNA methylation, nevi number, and the risk of melanoma.

Pergoli L, Favero C, Pfeiffer RM, Tarantini L, Calista D, Cavalleri T, Angelici L, Consonni D, Bertazzi PA, Pesatori AC, Landi MT, Bollati V.

Melanoma Res. 2014 Oct;24(5):480-7. doi: 10.1097/CMR.0000000000000112.

Supplemental Content

Loading ...
Support Center